Tags

Type your tag names separated by a space and hit enter

Once-daily amoxicillin versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis.
Arch Dis Child. 2008 Jun; 93(6):474-8.AD

Abstract

BACKGROUND

Rheumatic fever is a preventable chronic disease preceded by group A beta-haemolytic streptococcal (GABHS) pharyngitis.

OBJECTIVE

To test the non-inferiority of once-daily (QD) oral amoxicillin to the recommended twice-daily (BID) oral penicillin V in GABHS pharyngitis.

METHODS

This was a randomised non-inferiority trial carried out in a school-based clinic in New Zealand. Children presenting with GABHS pharyngitis were randomised to oral amoxicillin 1500 mg QD (or 750 mg if bodyweight was <or=30 kg) or to oral penicillin V 500 mg BID (or 250 mg if bodyweight was <or=20 kg) for 10 days. Observed medication and weekend diary cards were used to monitor adherence.

OUTCOME

Eradication of GABHS, determined with follow-up throat cultures on days 3-6, 12-16 and 26-36. GABHS isolates were serotyped to distinguish bacteriological treatment failures (and relapses) from new acquisitions. Non-inferiority was defined as an upper 95% confidence limit (CL) for the difference in success of eradication in the amoxicillin and penicillin V treatment groups of <or=10%.

RESULTS

353 children with positive throat swabs for GABHS were randomised to amoxicillin (n = 177) or penicillin V (n = 176). The upper 95% CL for the differences in positive cultures between the antibiotics was 4.9% at days 3-6, 6.5% at days 12-16 and 8.5% at days 26-36. Treatment failures (including relapses) occurred at each visit in 5.8%, 12.7% and 10.7% of amoxicillin recipients and 6.2%, 11.9% and 11.3% of penicillin V recipients, respectively. No significant differences in resolution of symptoms were noted between treatment groups. One case of unsubstantiated acute rheumatic fever occurred after 7 days of amoxicillin.

CONCLUSION

In this adequately powered study, once-daily oral amoxicillin is not inferior to twice-daily penicillin V for the treatment and eradication of GABHS in children with pharyngitis.

Authors+Show Affiliations

Department of Paediatrics, University of Auckland, Private Bag 92019, Auckland, New Zealand. d.lennon@auckland.ac.nzNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18337284

Citation

Lennon, D R., et al. "Once-daily Amoxicillin Versus Twice-daily Penicillin V in Group a Beta-haemolytic Streptococcal Pharyngitis." Archives of Disease in Childhood, vol. 93, no. 6, 2008, pp. 474-8.
Lennon DR, Farrell E, Martin DR, et al. Once-daily amoxicillin versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis. Arch Dis Child. 2008;93(6):474-8.
Lennon, D. R., Farrell, E., Martin, D. R., & Stewart, J. M. (2008). Once-daily amoxicillin versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis. Archives of Disease in Childhood, 93(6), 474-8. https://doi.org/10.1136/adc.2006.113506
Lennon DR, et al. Once-daily Amoxicillin Versus Twice-daily Penicillin V in Group a Beta-haemolytic Streptococcal Pharyngitis. Arch Dis Child. 2008;93(6):474-8. PubMed PMID: 18337284.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Once-daily amoxicillin versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis. AU - Lennon,D R, AU - Farrell,E, AU - Martin,D R, AU - Stewart,J M, Y1 - 2008/03/12/ PY - 2008/3/14/pubmed PY - 2008/6/21/medline PY - 2008/3/14/entrez SP - 474 EP - 8 JF - Archives of disease in childhood JO - Arch Dis Child VL - 93 IS - 6 N2 - BACKGROUND: Rheumatic fever is a preventable chronic disease preceded by group A beta-haemolytic streptococcal (GABHS) pharyngitis. OBJECTIVE: To test the non-inferiority of once-daily (QD) oral amoxicillin to the recommended twice-daily (BID) oral penicillin V in GABHS pharyngitis. METHODS: This was a randomised non-inferiority trial carried out in a school-based clinic in New Zealand. Children presenting with GABHS pharyngitis were randomised to oral amoxicillin 1500 mg QD (or 750 mg if bodyweight was <or=30 kg) or to oral penicillin V 500 mg BID (or 250 mg if bodyweight was <or=20 kg) for 10 days. Observed medication and weekend diary cards were used to monitor adherence. OUTCOME: Eradication of GABHS, determined with follow-up throat cultures on days 3-6, 12-16 and 26-36. GABHS isolates were serotyped to distinguish bacteriological treatment failures (and relapses) from new acquisitions. Non-inferiority was defined as an upper 95% confidence limit (CL) for the difference in success of eradication in the amoxicillin and penicillin V treatment groups of <or=10%. RESULTS: 353 children with positive throat swabs for GABHS were randomised to amoxicillin (n = 177) or penicillin V (n = 176). The upper 95% CL for the differences in positive cultures between the antibiotics was 4.9% at days 3-6, 6.5% at days 12-16 and 8.5% at days 26-36. Treatment failures (including relapses) occurred at each visit in 5.8%, 12.7% and 10.7% of amoxicillin recipients and 6.2%, 11.9% and 11.3% of penicillin V recipients, respectively. No significant differences in resolution of symptoms were noted between treatment groups. One case of unsubstantiated acute rheumatic fever occurred after 7 days of amoxicillin. CONCLUSION: In this adequately powered study, once-daily oral amoxicillin is not inferior to twice-daily penicillin V for the treatment and eradication of GABHS in children with pharyngitis. SN - 1468-2044 UR - https://www.unboundmedicine.com/medline/citation/18337284/Once_daily_amoxicillin_versus_twice_daily_penicillin_V_in_group_A_beta_haemolytic_streptococcal_pharyngitis_ DB - PRIME DP - Unbound Medicine ER -